Moolec Science (MLEC) Capital Expenditures (2023 - 2024)

Moolec Science's (MLEC) quarterly Capital Expenditures came in at -$4.1 million in Q4 2024, up 33.36% year-on-year from -$3.1 million in Q1 2024, and down 6734.62% quarter-over-quarter from -$59738.0 in Q3 2024.

Moolec Science (MLEC) Capital Expenditures (2023 - 2024) Analysis & Trends

Moolec Science has disclosed Capital Expenditures across 2 years of filings, most recently posting -$4.1 million for Q4 2024.

  • Capital Expenditures for Q4 2024 came in at -$4.1 million, up 33.36% year-over-year; the trailing twelve-month figure through Dec 2024 was $5.9 million (changed N/A YoY), and the FY2025 annual result was $5.7 million, down 43.12% from the prior year.
  • Capital Expenditures came in at -$4.1 million for Q4 2024 at Moolec Science, down from -$59738.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $11.5 million in Q2 2023 to a low of -$6.1 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn 133.40 Mn
9 Abivax 94.26 Bn 94.26 Bn - -63,220.27
10 Moolec Science 6.98 Bn 6.98 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -4.08 Mn
Dec 31, 2024 -4.08 Mn
Sep 30, 2024 -59,738.00
Sep 30, 2024 -59,738.00
Jun 30, 2024 10.06 Mn
Jun 30, 2024 10.06 Mn
Mar 31, 2024 -30,326.00
Mar 31, 2024 -30,326.00
Dec 31, 2023 -6.13 Mn
Dec 31, 2023 -6.13 Mn
Sep 30, 2023 -104,441.00
Sep 30, 2023 -104,441.00
Jun 30, 2023 11.49 Mn
Jun 30, 2023 11.49 Mn